* No difference in autoimmune adverse events of two vaccines
* Shares up 21 pct in premarket trade
March 23 Dynavax Technologies Corp (DVAX.O)
said the safety profile of its experimental hepatitis B vaccine
Heplisav was comparable with GlaxoSmithKline Plc's (GSK.L)
hepatitis B vaccine Engerix-B, which recently got a regulatory
The company said there was no difference in autoimmune
adverse events between subjects vaccinated with Heplisav and
Hepatitis B is a chronic disease, which can lead to
cirrhosis of the liver. There is no cure for the condition.
Dynavax is developing Heplisav for populations that are
less responsive to current licensed vaccines, including
individuals with chronic kidney disease.
In March 2008, U.S. Food and Drug Administration had put a
clinical hold on the vaccine. It is currently in late-stage
trials, after the FDA removed the hold last September.
Dynavax said the safety data was originally prepared for
regulatory submission as part of a documentation that formed
the basis upon which Heplisav's clinical development was
allowed to resume in late 2009.
Shares of the company were up 21 percent to $1.54 in
premarket trade. They closed at $1.27 Monday on Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Anil D'Silva)